Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates
01:27pm, Friday, 13'th Mar 2026
Capricor posted a quarterly loss of 62 cents per share, missing the consensus estimate of a 54-cent loss and worsening from a 16-cent loss in the prior-year period.
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
08:02pm, Thursday, 12'th Mar 2026
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
04:01pm, Thursday, 12'th Mar 2026
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise
Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review
10:47am, Tuesday, 10'th Mar 2026
Here's what investors need to know.
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
09:25am, Tuesday, 10'th Mar 2026
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
01:32pm, Monday, 09'th Mar 2026
The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center for Biologics Evaluation and Research (CBER), is set to leave his positio
GSA Capital Partners LLP Makes New $1.56 Million Investment in Capricor Therapeutics, Inc. $CAPR
04:16am, Wednesday, 18'th Feb 2026
GSA Capital Partners LLP purchased a new stake in Capricor Therapeutics, Inc. (NASDAQ: CAPR) in the third quarter, according to the company in its most recent filing with the Securities and Exchange C
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February
11:50am, Wednesday, 21'st Jan 2026
CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.
Maravai LifeSciences (NASDAQ:MRVI) & Capricor Therapeutics (NASDAQ:CAPR) Critical Review
01:10am, Monday, 12'th Jan 2026
Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Maravai LifeSciences (NASDAQ: MRVI - Get Free Report) are both small-cap medical companies, but which is the better business? We will contras
Here's Why This Biotechnology Skyrocketed by 439% in December
05:41am, Friday, 09'th Jan 2026
The Phase 3 trial met its primary and secondary endpoints. Management anticipates approval in 2026, with highly lucrative milestone payments expected to follow in the years to come.
Capricor Therapeutics (NASDAQ:CAPR) versus Glucose Health (OTCMKTS:GLUC) Head to Head Survey
01:26am, Wednesday, 31'st Dec 2025
Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Glucose Health (OTCMKTS:GLUC - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
Caprock Provides Update on Drilling and Announces Expansion of Drill Program at Its Destiny Gold Project
08:00am, Wednesday, 17'th Dec 2025
Toronto, Ontario--(Newsfile Corp. - December 17, 2025) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to provide an
Caprock Announces Closing of Private Placement and Confirmation of Payment of Anniversary Payment on Destiny Option
04:15pm, Friday, 12'th Dec 2025
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that
